JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Installé, J.
Right arrow Articles by Lonneux, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Installé, J.
Right arrow Articles by Lonneux, M.

18F-Fluoride PET for Monitoring Therapeutic Response in Paget’s Disease of Bone

Johanne Installé, MD1, Adrien Nzeusseu, MD2, Anne Bol, PhD1, Geneviève Depresseux2, Jean-Pierre Devogelaer, MD, PhD2 and Max Lonneux, MD, PhD

1 Department of Molecular Imaging and Experimental Radiotherapy, Catholic University of Louvain, Brussels, Belgium
2 Department of Rheumatology, Catholic University of Louvain, Brussels, Belgium



View larger version (66K):

[in a new window]
 
FIGURE 1. Illustration of the method used to draw ROIs on pagetic and normal contralateral bone. The region was manually drawn to closely encompass the area of highest uptake in the left ilium (on right side of axial image). A mirror ROI was drawn over contralateral nonaffected bone.

 


View larger version (13K):

[in a new window]
 
FIGURE 2. Correlations between SUVmax and Ki-PAT or Ki-NLR at baseline (A), 1 mo (B), and 6 mo (C) after start of treatment. All correlations were statistically significant (P < 0.05).

 


View larger version (15K):

[in a new window]
 
FIGURE 3. Relationship between change observed in SUVmax, Ki-PAT, and Ki-NLR between baseline and 1 mo after start of treatment (A and B) and between baseline and 6 mo after start of treatment (C and D). All correlations were statistically significant (P < 0.05).

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.